Evidence map›Paper›PMID 31428089›Full record

ReviewFrontiers in immunology2019

Fibroblast-Like Synoviocytes Glucose Metabolism as a Therapeutic Target in Rheumatoid Arthritis.

Patricia Gnieslaw de Oliveira, Mirian Farinon, Elsa Sanchez-Lopez, Shigeki Miyamoto, Monica Guma

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 129 citations in OpenAlex.

  1. Article
  2. JAK/STAT inhibition reprograms T cell activation and metabolism in inflammatory arthritis patients.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Energy metabolism in health and diseases.Signal transduction and targeted therapy · 2025
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Patricia Gnieslaw de OliveiraDepartment of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, United States.
Mirian FarinonDepartment of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, United States.
Elsa Sanchez-LopezPharmacology, School of Medicine, University of California, San Diego, La Jolla, CA, United States.
Shigeki MiyamotoPharmacology, School of Medicine, University of California, San Diego, La Jolla, CA, United States.
Monica GumaDepartment of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, United States.
University of California, San Diego · US

Funding

Targeting hexokinase-2 in rheumatoid arthritisR01AR073324 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUMA, MONICA · 2018 to 2022
$2.4M
NIAMS NIH HHS R01 AR073324
6 · The paper itself

Abstract

Metabolomic studies show that rheumatoid arthritis (RA) is associated with metabolic disruption that may be therapeutically targetable. Among them, glucose metabolism and glycolytic intermediaries seem to have an important role in fibroblast-like synoviocytes (FLS) phenotype and might contribute to early stage disease pathogenesis. RA FLS are transformed from quiescent to aggressive and metabolically active cells and several works have shown that glucose metabolism is increased in activated FLS. Glycolytic inhibitors reduce not only FLS aggressive phenotype

Indexed as

AnimalsArthritis, RheumatoidFibroblastsGlucoseHumansOsteoarthritisSynoviocytesGlucosefibroblast-like synoviocytesglucose metabolismglycolytic inhibitorshexokinase-2rheumatoid arthritis

Identifiers

PMID31428089
PMCPMC6688519
OpenAlexW2960795186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.